ARS Pharmaceuticals Inc. (SPRY) Cash Flow Statement Analysis - Operating Cash Flow, CapEx & Free Cash Flow - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    ARS Pharmaceuticals Inc.

    NASDAQ: SPRY · Real-Time Price · USD
    10.31
    0.03 (0.29%)
    At close: Oct 03, 2025, 3:59 PM
    10.63
    3.10%
    Pre-market: Oct 06, 2025, 04:42 AM EDT

    ARS Pharmaceuticals Cash Flow Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Net Income
    		 8M -54.37M -34.68M -20.24M
    Depreciation & Amortization
    		 -7.17M 73K 319K 6K
    Stock-Based Compensation
    		 14.53M 9.23M 5.84M 2.83M
    Other Working Capital
    		 -4.12M -4.55M -2.47M -6.39M
    Other Non-Cash Items
    		 n/a -6.88M 1.2M 207K
    Deferred Income Tax
    		 n/a n/a n/a -4K
    Change in Working Capital
    		 -1.81M -7.33M -12.75M -356K
    Operating Cash Flow
    		 13.55M -59.27M -40.08M -17.56M
    Capital Expenditures
    		 -563K -175K -199K -55K
    Cash Acquisitions
    		 n/a n/a n/a n/a
    Purchase of Investments
    		 -356.04M -272M n/a -65.11M
    Sales Maturities Of Investments
    		 258M 185M n/a n/a
    Other Investing Acitivies
    		 -7.5M n/a n/a 65.11M
    Investing Cash Flow
    		 -106.1M -87.18M -199K -55K
    Debt Repayment
    		 69.38M n/a -8.68M -1.82M
    Common Stock Repurchased
    		 n/a n/a n/a n/a
    Dividend Paid
    		 n/a n/a n/a n/a
    Other Financial Acitivies
    		 n/a n/a 198.84M 169K
    Financial Cash Flow
    		 72.4M 6.9M 190.73M 53.16M
    Net Cash Flow
    		 -20.15M -139.55M 150.46M 35.54M
    Free Cash Flow
    		 12.98M -59.44M -40.28M -17.62M

    Add to Watchlist